Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that treatment with ritlecitinib improved hair regrowth in alopecia areata patients, with many achieving significant results after 24 weeks compared to placebo.

This study reported that ritlecitinib was prescribed to a diverse group of patients with severe alopecia areata in the first 10 months after FDA approval, indicating its potential role in AA management.

This narrative review found that ritlecitinib shows consistent effectiveness and a favorable safety profile for treating alopecia areata in clinical trials and real-world settings, with progressive hair regrowth observed, particularly when treatment is initiated early and maintained appropriately.

In a mouse hair-growth model, this study found that the optimized compound 39 matched the efficacy of pyrilutamide for androgenic alopecia, with faster response and maintained safety, suggesting it as a promising topical AR antagonist with reduced systemic toxicity risk.

This study suggests that ROXYs and reactive oxygen species are likely involved in the signaling pathways plants use to respond to nitrate deprivation.

This study found that oxyresveratrol enhanced cell proliferation, reduced oxidative stress and inflammation in vitro, and promoted hair growth in an androgenetic alopecia mouse model, suggesting its potential as a treatment for hair loss.

In a single-center study, adolescents with moderate-to-severe alopecia areata treated with ritlecitinib 50 mg daily for 24 weeks showed significant hair regrowth, with 27.3% achieving near-complete regrowth and 45.5% substantial improvement, without serious safety concerns, according to these researchers.

In this study, ritlecitinib 50-mg showed clinically meaningful efficacy, with improvements in the Severity of Alopecia Tool score observed in patients with alopecia areata over a 3-year period, demonstrating long-term benefit in both clinician- and patient-reported outcomes.

Abrocitinib may help treat alopecia areata effectively with mild side effects.

In this study using a rabbit model, higher incidences of intraoperative floppy iris syndrome were observed in animals given the α-blocker tamsulosin, suggesting a potential association with increased iris billowing during eye surgery.

This article discusses the approval status of 5α-reductase inhibitors for androgenetic alopecia, noting finasteride is FDA-approved for certain men while dutasteride is not approved in the US for this condition; it reports no new results.

This study found that caffeic acid amide derivative, compound 4, effectively inhibited steroid 5α-reductase type 1 in vitro, suggesting potential for development as a treatment for androgenic alopecia.

This mini review explores the potential of herbal testosterone 5α-reductase inhibitors for treating androgenetic alopecia, suggesting they might offer fewer side effects and better tolerability than traditional treatments like finasteride and minoxidil.

This retrospective cohort study found that patients using 5α-reductase inhibitors had reduced bladder cancer-related mortality compared to nonusers, with no significant effect on bladder cancer recurrence or upper tract urothelial carcinoma mortality.

Oral 5-alpha reductase inhibitors do not increase breast cancer or benign breast disorder risk in women.

In this phase 2a study of adults with alopecia areata, researchers observed that ritlecitinib treatment did not result in significant differences in brainstem auditory evoked potential changes or axonal swelling compared to placebo, suggesting the dog toxicity findings may not be clinically relevant in humans.

This review discusses the relevance of human androgen receptor action in sports doping and examines the potential of cell-based biological assays for detecting androgenic anabolic steroid use, without presenting new research findings.

ROS may affect hair loss related to hormones.

In this retrospective cohort study, researchers found that patients with androgenetic alopecia using 5α-reductase inhibitors had a significantly higher risk of developing dry eye disease compared to those not using these medications.

This meta-analysis reports that 5-alpha-reductase inhibitors are associated with a 31% increased risk of depression, with varying outcomes depending on the comparator group, highlighting significant heterogeneity across studies.

This review discusses the structure, expression, regulation, and potential functions of the nuclear receptor coactivator NcoA4 in cancerous and non-cancerous pathologies, but reports no new results.

This study found that a chemically modified small-interfering RNA candidate, AR-27 E-Chol, effectively stimulated hair regrowth and reduced androgen receptor gene expression in a mouse model of androgenetic alopecia, indicating its potential as a novel therapeutic approach.

This review analyzes the mechanism and evidence supporting the approved use of ritlecitinib, a JAK3/TEC kinase inhibitor, for treating severe alopecia areata in patients aged 12 and older, highlighting its role in the changing therapeutic landscape of this immune-mediated disease.

This study identified novel selective androgen receptor modulators with enhanced in vivo pharmacological activity through structure-activity relationship analysis in castrated rats.

In this real-world study, 27% of alopecia areata patients treated with ritlecitinib achieved a target SALT score, a result consistent with clinical trial findings, highlighting the value of patient-reported outcomes in understanding treatment impact beyond traditional measures.

This study observed that local injection of minoxidil effectively prevented Ara-C-induced alopecia in newborn rats, while topical application was ineffective.

Ch55 may help reduce skin scarring and fibrosis.

This review discusses various compounds targeting the androgen receptor, including recent developments in heterobifunctional degraders for prostate cancer treatment, but reports no new clinical results.

This study reported that ritlecitinib 50 mg and baricitinib 4 mg showed similar efficacy in treating severe alopecia areata, with no significant difference in hair regrowth outcomes at Week 24, but there remains considerable uncertainty and a need for further research.

In this study, high-dose Arachis hypogaea root extract significantly reduced prostate weight and markers of glandular hyperplasia in testosterone-induced BPH in mice, with associated changes in inflammatory gene expression and beneficial shifts in gut microbiota.